Drugs / Anti-CD19 gene injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07211048 | Mar 2026 → Dec 2029 expected | B-cell neoplasm | Anhui Provincial Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD19 gene injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07211048 ↗ |
| Route | Intravenous | “Intravenous infusion of Anti-CD19 gene injection （three dosage groups）” NCT07211048 ↗ |
| Target | CD19 | “CD19-targeted Gene Injection” NCT07211048 ↗ |